Invesco
ATNM icon

Invesco’s Actinium Pharmaceuticals ATNM Stock Holding History

Invesco’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-153,555
Closed -$247K – 3770
2025
Q1 		$247K Buy
153,555
+141,130
+1,136% +$179K ﹤0.01% 3425
2024
Q4 		$15.7K Buy
12,425
+259
+2% +$402 ﹤0.01% 3747
2024
Q3 		$22.9K Buy
12,166
+166
+1% +$656 ﹤0.01% 3738
2024
Q2 		$88.8K Buy
12,000
+474
+4% +$3.9K ﹤0.01% 3768
2024
Q1 		$90.2K Sell
11,526
-35
-0.3% -$225 ﹤0.01% 3756
2023
Q4 		$58.7K Sell
11,561
-22,049
-66% -$114K ﹤0.01% 3741
2023
Q3 		$199K Buy
33,610
+20,500
+156% +$136K ﹤0.01% 3593
2023
Q2 		$97.3K Buy
+13,110
New +$112K ﹤0.01% 3731

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Invesco's ATNM Position: Q2 2025 in Review

Invesco sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 153,555 shares — an estimated $247K sold.

Invesco first reported a position in ATNM in Q2 2023 and held it in 8 quarters. The position peaked at $247K in Q1 2025. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Invesco reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 153,555 Actinium Pharmaceuticals shares in Q2 2025, an estimated $247K.
  • Invesco first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Invesco's Actinium Pharmaceuticals position peaked at $247K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.